Semaglutide vlogs on TikTok: separating real results from hype

What did @krunchymuffin actually say?

The creator is five weeks into semaglutide and documenting visible body changes using jeans as a measuring tool. That part is pretty straightforward. But the more medically interesting claim comes near the end: she says she started semaglutide not primarily for weight loss, but "to start regulating my PCOS" and her insulin levels, after being unable to tolerate metformin. She adds that weight loss was something that "just so happened" as a result.

This framing matters. It positions semaglutide as a metabolic management tool for PCOS, not just an appetite suppressant. That is a meaningfully different claim than most GLP-1 content on TikTok, and it deserves to be examined on its own terms rather than lumped in with generic weight loss content.

Does the science back this up?

Partially, yes, and more than you might expect. The evidence for GLP-1 receptor agonists in PCOS is real, but it is early and comes with caveats she does not mention.

A 2023 meta-analysis by Xu et al. in Frontiers in Endocrinology found that GLP-1 receptor agonists significantly reduced fasting insulin, HOMA-IR scores, and testosterone levels in women with PCOS compared to controls. A smaller but well-designed 2022 RCT by Jensterle et al. in Reproductive Biology and Endocrinology compared liraglutide directly to metformin in PCOS patients and found comparable improvements in insulin sensitivity, with liraglutide showing better tolerability in those with GI issues related to metformin.

So her core logic is not wrong. GLP-1 agonists do appear to improve insulin resistance in PCOS, which is a driver of many PCOS symptoms. But semaglutide specifically has far less PCOS trial data than liraglutide, and no GLP-1 drug has FDA approval for PCOS management. That gap between "the science supports the mechanism" and "this is an approved treatment" is one she skips over entirely.

What did they get wrong (or right)?

She gets the mechanistic logic right. PCOS is frequently driven by insulin resistance, metformin works by improving insulin sensitivity, and GLP-1 receptor agonists also improve insulin sensitivity through different pathways. If someone cannot tolerate metformin, a GLP-1 agonist is a clinically plausible alternative that some endocrinologists do use off-label.

What she gets wrong, or at least leaves dangerously incomplete, is the implication that semaglutide is a straightforward substitute for metformin in PCOS. Metformin has decades of safety data in PCOS, including data on ovulation restoration and pregnancy outcomes. Semaglutide does not. Women with PCOS who are trying to conceive or who have reproductive goals need to know that semaglutide carries a contraindication during pregnancy and that its effects on ovulation restoration, while promising in early data, are not well characterized yet.

She also does not mention that "regulating insulin levels" in PCOS is not the same as treating PCOS. Symptom improvement is not remission. A video with 670K views probably should have that caveat somewhere.

What should you actually know?

If you have PCOS and cannot tolerate metformin, GLP-1 receptor agonists are a legitimate conversation to have with your doctor. The mechanism is sound and the early trial data is encouraging. But there are things the vlog format will not tell you.

• Semaglutide is not FDA-approved for PCOS. Any use in that context is off-label, which does not make it wrong, but it does mean less regulatory oversight of how it is prescribed.
• Weight loss alone can improve PCOS symptoms independent of the drug itself. Studies like the one by Kiddy et al. have shown that even a 5 percent body weight reduction restores ovulation in some women with PCOS. Separating the drug's direct metabolic effect from its weight-loss effect is hard to do in a five-week vlog.
• If you are of reproductive age and on semaglutide, you need to discuss contraception with your prescriber. Improved insulin sensitivity can restore ovulation in PCOS, sometimes unexpectedly, and semaglutide is not safe during pregnancy.
• Metformin intolerance is real, but the extended-release formulation resolves GI side effects in a significant percentage of patients. She says she tried it, which is worth taking at face value, but it is worth confirming that distinction was explored with a provider.